Monday, January 25, 2016
Carnegie Mellon Team Develops Targeted Photosensitizer for Cell Manipulation
Technology Could Be Used To Better Understand and Treat Disease
Zebrafish larvae expressing FAP in the heart are treated with a normal fluorogen (left) or the targeted, activated photosensitizer (TAPS-right), then exposed to light and followed for 3 days. Only the TAPS-treated fish show defects associated with loss of cardiac function after photoablation, including loss of cardiac tissues (blue), cardiac edema, and other developmental defects.
Researchers led by Carnegie Mellon University’s Molecular and Biosensor Imaging Center (MBIC) Director Marcel Bruchez have re-engineered a fluorescent probe into a powerful optogenetic photosensitizer that can be used to manipulate cells.
The technology could help researchers better understand the role certain cells and proteins play in everyday function and disease, and could possibly be used as a targeted therapy for cancer and other diseases. Their findings were published online today by Nature Methods.
Optogenetics refers to a process in which light is used to control a biological function. Researchers do this by programming light-activated components into an organism’s genetic code. When those components are exposed to light, they cause parts of the organism to function differently.
Bruchez and his team have spent the past decade developing fluorescent probes called fluorogen-activating proteins (FAPs) that are used to monitor protein activity in living cells in real-time. A FAP is genetically expressed in a cell and can be linked to the particular protein researchers wish to study. When a FAP comes in contact with a fluorescent dye called a fluorogen, the complex lights up allowing researchers to view and track the protein.
“We realized that we didn’t have to limit our technology to being an imaging tool,” said Bruchez, who is an associate professor in the departments of Biological Sciences and Chemistry. “With a few modifications, we could transform it into a tool for biological manipulation.”
To create their optogenetic tag, the researchers engineered a dye that would not only glow but also produce singlet oxygen — a toxic form of oxygen — when it bound to a FAP and was exposed to light. This FAP-Targeted and Activated PhotoSensitizer approach (FAP-TAPS) not only allows researchers to visualize the protein they are targeting, but also can be used to selectively inactivate the protein.
Previous attempts at developing such photosensitizers have been limited by their inability to selectively bind to target proteins and their need for high doses of light at biologically damaging wavelengths. The FAP-TAPS complex overcomes these obstacles with the precise targeting features of FAPs and the use of light in the far-red or near-infrared spectrums. Light at these wavelengths is both tissue penetrating and biologically safe. The FAP-TAPS approach also requires significantly less light than other photosensitizers, like Killer Red. In addition, singlet oxygen is biologically reactive over a short range, so it doesn’t harm proteins in other areas of the cell, or cells in other areas of the organism.
In the paper, the researchers proved the effectiveness of the FAP-TAPS module in a population of zebrafish. They first created a fish that expressed the FAP module only in cardiac muscle cells. They then added the dye and exposed the fish to light. In larval fish, the effects were immediate — the heart stopped beating and the blood flow ceased. In adult fish, the fish displayed a cardio-toxic response, and began to transform cardiomyocytes into proliferating cells, which repaired the damage within days. In addition to the proof-of-concept, the results show that FAP-TAPS could be used to study cardiac regeneration in zebrafish.
The researchers also believe that FAP-TAPS has the potential to be used for a variety of other purposes, both health-related and in basic research. Such areas include tumor ablation, reactive oxygen signaling and the manipulation of the nervous system.
Additional authors on the study include Carnegie Mellon’s Jianjun He, Yi Want and Lydia A. Perkins; and the University of Pittsburgh’s Maria A. Missinato, Ezenwa Onuoha, Simon C. Watkins, Cladette M. St. Croix and Michael Tsang.
The research was funded by the National Institutes of Health, Technology Centers for Networks and Pathways Program (GM103529, EB017268 & ES025606).
By: Jocelyn Duffy, email@example.com, 412-268-9982